Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway

Almonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC). However, the development of resistance inevitably occ...

Full description

Bibliographic Details
Main Authors: Chen Shi, Cong Wang, Zhiwen Fu, Jinmei Liu, Yuanfeng Zhou, Bao Cheng, Cong Zhang, Shijun Li, Yu Zhang
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Pharmacological Research
Subjects:
LCN2
MMP-9
Pyroptosis
Almonertinib
Resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S104366182400032X

Similar Items

Similar Items